Everest Medicines (SEHK:1952): Revisiting Valuation After Recent Share Price Weakness

Everest Medicines (SEHK:1952) inched up about 2% in the latest session, a small move that still draws attention given the stock’s weaker performance over the past 3 months and year.

See our latest analysis for Everest Medicines.

At HK$44.84, the latest move comes against a weak backdrop, with the 30 day share price return of negative 5.9% and a much steeper 90 day share price return of negative 23%. This suggests recent momentum is fading despite a robust three year total shareholder return of more than 230%.

If Everest’s swings have you rethinking concentration risk, it could be worth scanning other healthcare names and discovering healthcare stocks for fresh ideas in the same space.

With analysts still seeing nearly 45% upside and our intrinsic estimates implying an even steeper discount, the big question now is whether Everest Medicines is genuinely undervalued or if markets are already pricing in its future growth.

Most Popular Narrative Narrative: 30.5% Undervalued

With the narrative fair value sitting meaningfully above the last close, the valuation hinges on Everest turning steep losses into sustained profitability.

The company's robust and diversified pipeline spanning mRNA vaccines, in vivo CAR-T, and novel autoimmune therapies with multiple assets moving toward late-stage trials positions Everest to benefit from global moves toward precision and targeted medicines, driving long-term revenue streams and earnings growth from innovative products.

Read the complete narrative.

Curious how a loss making biotech commands such a premium? The story leans on explosive revenue, sharply higher margins, and a bold future earnings multiple. Want to see exactly how those pieces fit together?

Result: Fair Value of $64.56 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, sustained heavy R&D spend and Everest’s reliance on NEFECON mean any clinical setback or pricing pressure could quickly challenge this optimistic valuation path.

Find out about the key risks to this Everest Medicines narrative.

Build Your Own Everest Medicines Narrative

If you would rather challenge these assumptions and dig into the numbers yourself, you can build a fully custom Everest Medicines view in minutes, Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Everest Medicines.

Looking for more investment ideas?

Before you move on, lock in fresh opportunities by using the Simply Wall St Screener to spot stocks with real potential, not just passing hype.

• Target rapid movers on the edge of major re-ratings by scanning these 3612 penny stocks with strong financials showing improving balance sheets and credible growth stories.
• Position yourself at the heart of the AI transformation by focusing on these 26 AI penny stocks poised to turn algorithms into lasting competitive advantages.
• Strengthen your core portfolio with these 908 undervalued stocks based on cash flows that combine solid cash flows with prices that still sit meaningfully below intrinsic value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com